SCHEMBL22018461

SCHEMBL22018461

O=C1CCC2(CNc3ccccc32)C(=O)N1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 2/20 0.54
NPC1 O15118 1/20 0.40
MAPK13 O15264 1/20 0.40
MAPK12 P53778 1/20 0.40
MAPK11 Q15759 1/20 0.40
MAPK14 Q16539 1/20 0.40
OPRM1 P35372 1/20 0.38
OPRK1 P41145 1/20 0.38
OPRL1 P41146 1/20 0.38
MAPT P10636 1/20 0.38
PDK2 Q15119 1/20 0.36
PDK4 Q16654 1/20 0.36
HTR1A P08908 1/20 0.35
HTR2A P28223 1/20 0.35
HTR7 P34969 1/20 0.35
HTR6 P50406 1/20 0.35
TNKS O95271 2/20 0.35
TNKS2 Q9H2K2 2/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3363788 0.87 BACE1 (0.62) BACE1OPRM1OPRK1OPRL1PDK2
SCHEMBL30548894 0.81 BACE1 (0.46) BACE1NPC1MAPK13MAPK12MAPK11
SCHEMBL26124000 0.80 BACE1 (0.61) BACE1OPRM1OPRK1OPRL1PDK2
SCHEMBL19586536 0.79 CA9 (0.49) BACE1MAPTMEN1KMT2AGAA
SCHEMBL22018462 0.77 BACE1 (0.54) BACE1OPRM1OPRK1OPRL1PDK2
SCHEMBL11959109 0.73 BACE1 (0.57) BACE1OPRM1OPRK1OPRL1PDK2
SCHEMBL1924203 0.73 BACE1 (0.60) BACE1OPRM1OPRK1OPRL1PDK2
SCHEMBL29386355 0.73 BACE1 (0.60) BACE1OPRM1OPRK1OPRL1PDK2
Alonimid SCHEMBL114140 0.72 CRBN (0.38) BACE1OPRM1OPRK1OPRL1MEN1
Alonimid SCHEMBL29728701 0.72 CRBN (0.38) BACE1OPRM1OPRK1OPRL1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11185592-B2 Spirocyclic degronimers for target protein degradation C4 THERAPEUTICS, INC. (US) 2021-11-30 US disclosed
US-20210106688-A1 SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2021-04-15 US disclosed
US-10660968-B2 Spirocyclic degronimers for target protein degradation C4 THERAPEUTICS, INC. (US) 2020-05-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11185592-B2 Spirocyclic degronimers for target protein degradation STUB1, UBE3C, UBE3A BACE1 1584/4885NPC1 2188/4885MAPK13 1782/4885
US-20210106688-A1 SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION STUB1, UBE3C, UBE3A BACE1 1584/4885NPC1 2188/4885MAPK13 1782/4885
US-10660968-B2 Spirocyclic degronimers for target protein degradation STUB1, UBE3C, UBE3A BACE1 1584/4885NPC1 2188/4885MAPK13 1782/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.